Literature DB >> 12502876

Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody.

Laurence Cocquerel1, Elizabeth R Quinn, Mike Flint, Kenneth G Hadlock, Steven K H Foung, Shoshana Levy.   

Abstract

The majority of hepatitis C virus (HCV)-infected individuals progress from acute to chronic disease, despite the presence of a strong humoral immune response to the envelope glycoproteins E1 and E2. When expressed in mammalian cells, E1 and E2 form both noncovalently linked E1E2 heterodimers, believed to be properly folded, and disulfide-linked, high-molecular-weight aggregates that are misfolded. Previously, we identified 10 human monoclonal antibodies (HMAbs) that bind E2 glycoproteins from different genotypes. Here we demonstrate that one of these HMAbs, CBH-2, is unique in its ability to distinguish between properly folded and misfolded envelope proteins. This HMAb recognizes HCV-E2 only when complexed with E1. The E1E2 complexes recognized by CBH-2 are noncovalently linked heterodimers and not misfolded disulfide-linked, high-molecular-weight aggregates. The E1E2 heterodimers seen by CBH-2 no longer associate with the endoplasmic reticulum chaperone calnexin and are likely to represent the prebudding form of the HCV virion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502876      PMCID: PMC140849          DOI: 10.1128/jvi.77.2.1604-1609.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum.

Authors:  Mike Flint; Jane A McKeating
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

2.  Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface.

Authors:  X Forns; T Allander; P Rohwer-Nutter; J Bukh
Journal:  Virology       Date:  2000-08-15       Impact factor: 3.616

3.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization.

Authors:  A Op De Beeck; R Montserret; S Duvet; L Cocquerel; R Cacan; B Barberot; M Le Maire; F Penin; J Dubuisson
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

5.  The transmembrane domain of the hepatitis C virus E2 glycoprotein is required for correct folding of the E1 glycoprotein and native complex formation.

Authors:  J Patel; A H Patel; J McLauchlan
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

6.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

Authors:  J M Heile; Y L Fong; D Rosa; K Berger; G Saletti; S Campagnoli; G Bensi; S Capo; S Coates; K Crawford; C Dong; M Wininger; G Baker; L Cousens; D Chien; P Ng; P Archangel; G Grandi; M Houghton; S Abrignani
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein.

Authors:  J Dubuisson; S Duvet; J C Meunier; A Op De Beeck; R Cacan; C Wychowski; L Cocquerel
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

9.  Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins.

Authors:  L Cocquerel; C Wychowski; F Minner; F Penin; J Dubuisson
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

10.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

View more
  16 in total

1.  Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.

Authors:  Shazia Rafique; Muhammad Idrees; Amjad Ali; Muhammad Iqbal
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

Review 2.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

3.  Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.

Authors:  Alexander W Tarr; Richard A Urbanowicz; Mohamed R Hamed; Anna Albecka; C Patrick McClure; Richard J P Brown; William L Irving; Jean Dubuisson; Jonathan K Ball
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

4.  Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.

Authors:  Juliano G Haddad; Yves Rouillé; Xavier Hanoulle; Véronique Descamps; Monzer Hamze; Fouad Dabboussi; Thomas F Baumert; Gilles Duverlie; Muriel Lavie; Jean Dubuisson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Authors:  Muriel Lavie; Stéphane Sarrazin; Roland Montserret; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Karin Séron; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

7.  Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.

Authors:  Zhen-Yong Keck; Vicky M H Sung; Susan Perkins; Judy Rowe; Sudhir Paul; T Jake Liang; Michael M C Lai; Steven K H Foung
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.

Authors:  Daniel X Johansson; Cécile Voisset; Alexander W Tarr; Mie Aung; Jonathan K Ball; Jean Dubuisson; Mats A A Persson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

9.  Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.

Authors:  Zhen-Yong Keck; Anne Op De Beeck; Kenneth G Hadlock; Jinming Xia; Ta-Kai Li; Jean Dubuisson; Steven K H Foung
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein.

Authors:  Ahmed Wahid; François Helle; Véronique Descamps; Gilles Duverlie; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.